Related Experiment Video
Updated: May 18, 2026
10:56
Quantifying Infra-slow Dynamics of Spectral Power and Heart Rate in Sleeping Mice
Published on: August 2, 2017
Adenosine deaminase polymorphism affects sleep EEG spectral power in a large epidemiological sample
Diego Robles Mazzotti1, Camila Guindalini, Altay Alves Lino de Souza
1Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, Brazil.
Plos One
|September 7, 2012
Summary
The adenosine deaminase gene (ADA G22A) polymorphism influences sleep intensity. A allele carriers exhibit higher delta and theta electroencephalogram (EEG) spectral power, suggesting more intense sleep and impacting sleep homeostasis.
Area of Science:
- Neuroscience
- Genetics
- Sleep Medicine
Background:
- Slow wave oscillations in electroencephalogram (EEG) during sleep are linked to sleep need and homeostatic regulation.
- Adenosine plays a key role in sleep homeostasis, with the adenosine deaminase gene (ADA G22A) polymorphism previously associated with improved sleep quality.
Purpose of the Study:
- To investigate the association between the ADA G22A polymorphism and sleep EEG spectral power.
- To determine if this genetic variation influences objective measures of sleep intensity and homeostasis.
Main Methods:
- Analysis of full-night polysomnography and ADA G22A genotyping in 800 individuals from the Epidemiologic Sleep Study (EPISONO).
- Spectral analysis of EEG signals using fast Fourier transformation.
- Comparison of genotype groups in the whole sample and a matched subsample.
Main Results:
- Individuals with the A allele of the ADA G22A polymorphism showed significantly higher delta spectral power in Stage 1 and Stages 3+4 sleep.
- Increased theta spectral power was observed in Stages 1, 2, and REM sleep for A allele carriers.
- These findings were consistent across the entire sample and a matched subset.
Conclusions:
- The ADA G22A polymorphism is associated with increased EEG spectral power, indicating potentially more intense sleep.
- This genetic variation may contribute to individual differences in human sleep homeostasis through modulation of EEG activity.
More Related Videos
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:13Insufficient Sleep and Sleep Deprivation
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
Sleep deprivation is a more severe form of sleep loss...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:21Sleep Apnea
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
02:19Circadian Rhythms and Gene Regulation
The biological clock is involved in many aspects of regulating complex physiology in all animals. It was in 1935 when German zoologists, Hans Kalmus and Erwin Bünning, discovered the existence of circadian rhythm in Drosophila melanogaster. However, the internal molecular mechanisms behind the circadian clock remained a mystery until 1984, when Jeffrey C. Hall, Michael Rosbash, and Michael W. Young discovered the expression of the Per gene oscillating over a 24-hour cycle. In subsequent years,...